Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease.
Seven males with atherosclerotic disease received daily 1.6 g of the thromboxane antagonist BM 13.177 in two separate oral dosages over a period of four days. The drug significantly reduced elevated plasma levels of thromboxane B2, beta-thromboglobulin and platelet factor 4, whereas thromboxane B2 generation was only slightly depressed. BM 13.177 inhibited platelet aggregation by collagen, and to a minor degree the second wave of ADP induced aggregation. Platelet sensitivity to prostacyclin and aggregation by ristocetin were not altered. Bleeding time was prolonged. All effects disappeared within 24 hours after the last application of the drug. No side effects were noted. Thus BM 13.177 appears to be a safe and effective new antiplatelet drug.
D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010978:Platelet Factor 4 / Q000032:analysis; D013449:Sulfonamides / Q000097:blood / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism
D005343:Fibrinolytic Agents; D013449:Sulfonamides; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D013929:Thromboxane B2; C040624:sulotroban